Synergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosy

@article{Oliveira2014SynergisticAC,
  title={Synergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosy},
  author={R. M. Oliveira and Emerith Mayra Hungria and A. Ara{\'u}jo Freitas and Ana L{\'u}cia Maroclo Sousa and M B Costa and Steven G. Reed and Malcolm S. Duthie and Mariane Martins Ara{\'u}jo Stefani},
  journal={European Journal of Clinical Microbiology \& Infectious Diseases},
  year={2014},
  volume={33},
  pages={1415-1424}
}
The development of immunodiagnostic tests for paucibacillary leprosy (PB) is based on Mycobacterium leprae specific-cell mediated immunity (CMI)/IFN-γ production. Recently, novel M. leprae protein antigens that stimulate CMI have been described. This study evaluated different M. leprae antigen combinations in whole blood assay (WBA). Five study groups were tested (20 per group): newly diagnosed, untreated PB patients and multibacillary leprosy patients (MB); household contacts of MB patients… 

Alterations to antigen-specific immune responses before and after multidrug therapy of leprosy.

Host immune responses induced by specific Mycobacterium leprae antigens in an overnight whole-blood assay correlate with the diagnosis of paucibacillary leprosy patients in China

TLDR
It is suggested that the host markers induced by specific M. leprae antigens in an overnight WBA increase diagnostic and discriminatory value in PB patients with leprosy, with a particularly strong association with interleukin 8.

Transcriptomic Analysis of Mycobacterium leprae-Stimulated Response in Peripheral Blood Mononuclear Cells Reveal Potential Biomarkers for Early Diagnosis of Leprosy

TLDR
Among the 12 candidate host genes identified, a three gene signature IL-8, CCL2/MCP-1, SERP, and SERP showed the best performance in distinguishing leprosy patients from healthy controls.

Leprosy surveillance study in a highly endemic Brazilian area using leprosy specific serologic tests and IFNγ whole blood assay

TLDR
This surveillance study evaluated leprosy-serologic tests and the IFNγ whole-blood-assay/WBA as adjunct diagnostic tools and found the utility of serologic screening for surveillance and prophylactic measures remains to be demonstrated.

Evaluation of Novel Tools to Facilitate the Detection and Characterization of Leprosy Patients in China

TLDR
The data support the use of antibody detection tests and WBA to facilitate the diagnosis of multibacillary and paucIBacillary leprosy, respectively and could be invaluable for increased, but simplified, monitoring of individuals in order to provide referrals for clinical exam and early leproSy diagnosis.

Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy

TLDR
Simple assays measuring biomarkers as surrogates for disease development or replacements for invasive, but not particularly sensitive, direct measures of M. leprae infection are discussed, which could facilitate the clinical trials required to develop these new chemoprophylaxis, immunopophylaxis strategies, and transition into wider use.

Serum Antibody Reactivity of Leprosy Patients Attending a Dermatology Clinic in Caracas , Venezuela

TLDR
The data indicate that many patients attending the clinic have advanced M. leprae infection and disease presentation, with the detection of circulating antibodies having the potential to facilitate referrals for clinical diagnosis of leprosy in Venezuela.

Quantiferon-Gold Tuberculosis Test Cannot Detect Latent Tuberculosis in Patients With Leprosy.

  • Tina RendiniW. Levis
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2015
TLDR
Five of 10 paucibacillary leprosy patients were Quantiferon Gold (Q-G) positive with negative chest X-rays, and reports have shown 100% cross-reactivity of ESAT6 and CFP10 between Myc Cobacterium leprae and Mycobacterium tuberculosis.

References

SHOWING 1-10 OF 47 REFERENCES

Identification of Specific Proteins and Peptides in Mycobacterium leprae Suitable for the Selective Diagnosis of Leprosy1

TLDR
Comparison genome analysis to identify genes that are specific to Mycobacterium leprae are identified and synthetic peptides from a subset of these are tested for immunological reactivity, indicating that CD8+ T cell epitopes may also have diagnostic potential.

Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development

TLDR
New M. leprae antigens recognized by antibody responses of BL/LL patients and cellular responses of TT/BT leprosy patients were identified and the WBA is a robust, relatively simple and user friendly format for a T cell based diagnostic test.

Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy

TLDR
While none of the biomarkers tested could discriminate leprosy patients from HHC, the data indicate that, although most HHC antigen-specific responses are qualitatively similar to TT/BT patients, some HHC can respond similarly to BL/LL patients.

Towards an immunodiagnostic test for leprosy.

ML0405 and ML2331 Are Antigens of Mycobacterium leprae with Potential for Diagnosis of Leprosy

TLDR
Results suggest that ML0405 and ML2331 may have utility in serological leprosy diagnosis, and the provision of highly specific serological antigens that may be combined with PGL-I to improve the sensitivity of diagnosis.

Enhancing Sensitivity of Detection of Immune Responses to Mycobacterium leprae Peptides in Whole-Blood Assays

TLDR
It is found that only interleukin 12 (IL-12), not other costimulants, increased IFN-γ production in WBA while maintaining M. leprae peptide specificity, as evidenced by lack of increase of IFn-γ in control samples stimulated with IL-12 alone.

Use of Protein Antigens for Early Serological Diagnosis of Leprosy

TLDR
It is determined that LID-1 was capable of diagnosing leprosy 6 to 8 months before the onset of clinical symptoms and that the geographic locations of the patients can influence the antigens they recognize but that ML0405 and ML2331 are recognized by sera from diverse regions.

Diagnostic assays for leprosy based on T-cell epitopes.

TLDR
A Leprosy Synthetic Peptide Skin Test Initiative was established to investigate the potential of synthetic peptides that encode T-cell epitopes as diagnostic tools, which could be used to develop a skin-test reagent specific for leprosy.

New Biomarkers with Relevance to Leprosy Diagnosis Applicable in Areas Hyperendemic for Leprosy

TLDR
M. leprae-unique Ags, particularly ML2478, are identified as biomarker tools to measure M. lePrae exposure and it is shown that MCP-1, MIP-1 β, and IL-1β can potentially distinguish pathogenic immune responses from those induced during asymptomatic exposure to M.Leprosy.

Selection of Antigens and Development of Prototype Tests for Point-of-Care Leprosy Diagnosis

TLDR
Analysis of serologic antibody response to identify Mycobacterium leprae proteins that are recognized by leprosy patients indicates that multibacillary patients can be distinguished from paucibACillary patients, and both of these groups can be segregated from endemic control groups.